The Daily Buyout
$18MDivestiture / carve-outHealthcare & Life Sciences

RedHill Divests Talicia to Apotex for $18 Million Upfront

RedHill Biopharma agreed to sell its Talicia business to a subsidiary of Apotex Health Corp. for $18 million upfront plus up to $35 million in net sales milestone payments.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals